Treatment with Alorica (Alorica) should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).Its use should be individualized for each patient and requires an understanding of its mode of action and pharma-cokinetics. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA.Īlorica (Alorica) reduces serum and urinary uric acid concentrations.
0 kommentar(er)
